
Biofrontera is a biopharmaceutical company that develops and distributes dermatological drugs, with Ameluz® its lead prescription drug for photodynamic therapy.
biofrontera.comCrawled Nov 20, 2026
Biofrontera AG partners with Propaira Pty Ltd to distribute **Ameluz** in Australia, pending regulatory approval. The agreement marks an early step in the company’s expanded commercialization strategy for the photodynamic therapy product. Distribution is planned for the first half of 2028, contingent on successful registration.
Biofrontera AG reports a €9.0 million revenue increase (44% YoY) in H1 2026, reaching €9.0M, alongside a €5.5M profit after tax. The company’s EBITDA from continuing operations stands at €1.7M, reflecting improved financial performance. The guidance for 2026 remains unchanged.
Biofrontera AG reports **€9.0 million in H1 2026 revenue**, a 44% year-over-year increase, alongside **€1.7 million in EBITDA**—marking its first positive EBITDA from continuing operations. The company’s net profit reaches **€5.5 million**, influenced by discontinued operations and earn-out adjustments. The financial shift reflects a strategic pivot toward European markets.
Biofrontera AG begins two clinical studies for its prescription drug **Ameluz®** in the U.S. Seven sites are enrolling patients for a **Phase II trial** targeting moderate-to-severe acne in adults. Eight additional sites are initiating a **Phase I safety study** to evaluate the drug’s tolerability.
Biofrontera AG schedules a conference call to discuss its **half-year 2021 financial results** for the period ending **June 30, 2021**. The biopharmaceutical company will release its performance updates on **August 19, 2021**. The event provides stakeholders with insights into revenue, operational progress, and strategic outlook for its dermatology-focused therapies.